Mass spectrometry proteomic biomarkers identify acute COPD exacerbations
O. Elneima (Leicester, United Kingdom), T. Cao (Leicester, United Kingdom), H. Mcauley (Leicester, United Kingdom), M. Ramsheh (Leicester, United Kingdom), V. Mistry (Leicester, United Kingdom), N. Greening (Leicester, United Kingdom), L. Ng (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom)
Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Elneima (Leicester, United Kingdom), T. Cao (Leicester, United Kingdom), H. Mcauley (Leicester, United Kingdom), M. Ramsheh (Leicester, United Kingdom), V. Mistry (Leicester, United Kingdom), N. Greening (Leicester, United Kingdom), L. Ng (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom). Mass spectrometry proteomic biomarkers identify acute COPD exacerbations. 2989
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: